Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 08 20; 39(24):2647-2655.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Female
Humans
Ipilimumab
Male
Melanoma
Middle Aged
authors with profiles
Bruce E. Brockstein
Thomas N. Krausz
Theodore Karrison
Thomas F. Gajewski
Timothy Carll